文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience.

作者信息

Kolla Gillian, Fajber Kaitlin, Sereda Andrea, Morris Cassidy, Deacon Perri, Cipriano Lauren E

机构信息

Faculty of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada.

Canadian Institute for Substance Use Research, University of Victoria, Victoria, British Columbia, Canada.

出版信息

Drug Alcohol Depend Rep. 2025 Apr 23;15:100338. doi: 10.1016/j.dadr.2025.100338. eCollection 2025 Jun.


DOI:10.1016/j.dadr.2025.100338
PMID:40416078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12098166/
Abstract

INTRODUCTION: Safer opioid supply (SOS) is a harm reduction approach to prescribing pharmaceutical opioids to people at high risk of overdose from the toxic unregulated drug supply. Previous research demonstrates positive health outcomes and reductions in overdose mortality among SOS clients; however few reports describe previous opioid agonist treatment history prior to initiating SOS, or the medication combinations and doses prescribed within SOS programs. METHODS: We used convenience sampling to collect survey data from 95 SOS program clients in London, Canada. We use descriptive statistics to analyze survey data and report on OAT history prior to initiating SOS, including maximum methadone dose. We also report on current SOS medication combinations and doses. FINDINGS: Previous experience with OAT was common and reported by 87 % of SOS clients. Mean highest dose of methadone ever received was 95 mg (range: 20-200 mg), with close to 40 % reporting doses of ≥ 120 mg. 95 % of SOS clients reported prescriptions for immediate-release tablet hydromorphone; 28 % were receiving hydromorphone monotherapy; 68 % were receiving hydromorphone alongside a long-acting opioid, and 5 % receiving hydromorphone alongside 2 long-acting opioids. Total average milligram morphine equivalent (MME) doses of combination SOS prescriptions (MME 1616) were similar to high dose methadone (120 mg = MME 1440). CONCLUSIONS: Previous high dose OAT experience was common among SOS clients prior to enrollment in the SOS program. Our results may inform the individualization of high dose opioid prescriptions for people with high tolerance due to exposure to unregulated fentanyl.

摘要

相似文献

[1]
Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience.

Drug Alcohol Depend Rep. 2025-4-23

[2]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[3]
Comprehensive substance use services within primary care settings: The Safer Opioid Supply program at London InterCommunity Health Centre.

Can J Public Health. 2025-3-12

[4]
Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.

Int J Drug Policy. 2022-4

[5]
'I don't chase drugs as much anymore, and I'm not dead': Client reported outcomes associated with safer opioid supply programs in Ontario, Canada.

Drug Alcohol Rev. 2023-11

[6]
Preferred pharmaceutical-grade opioids to reduce the use of unregulated opioids: A cross-sectional analysis among people who use unregulated opioids in Vancouver, Canada.

Int J Drug Policy. 2024-10

[7]
Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis.

Can J Public Health. 2024-12-10

[8]
Early experiences and impacts of a fentanyl powder safer supply program in Vancouver, Canada: a qualitative study.

Am J Drug Alcohol Abuse. 2025-5-6

[9]
Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies.

Int J Drug Policy. 2023-5

[10]
Comparing the effects of prescribed safer opioid supply and methadone in Ontario, Canada: a population-based matched cohort study.

Lancet Public Health. 2025-5

本文引用的文献

[1]
Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis.

Can J Public Health. 2024-12-10

[2]
Management of opioid use disorder: 2024 update to the national clinical practice guideline.

CMAJ. 2024-11-11

[3]
Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

JAMA. 2024-12-3

[4]
"If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.

Harm Reduct J. 2024-6-7

[5]
Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt.

JAMA Netw Open. 2024-5-1

[6]
Prescribed safer opioid supply: A scoping review of the evidence.

Int J Drug Policy. 2024-3

[7]
Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.

BMJ. 2024-1-10

[8]
Association of random and observed urine drug screening with long-term retention in opioid treatment programs.

Drug Alcohol Depend. 2024-2-1

[9]
'I don't chase drugs as much anymore, and I'm not dead': Client reported outcomes associated with safer opioid supply programs in Ontario, Canada.

Drug Alcohol Rev. 2023-11

[10]
Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis.

Int J Drug Policy. 2023-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索